Safety analysis of luteolin for prostate cancer

JRCT ID: jRCTs041230029

Registered date:31/05/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: prostate cancer patients
• Date of first enrollment: 22/06/2023
• Target sample size: 10
• Study type: Interventional
• Intervention(s): Orally taking luteolin 100mg for 24 weeks

Outcome(s)

• Primary Outcome: incidence and severity in adverse events
• Secondary Outcome: PSA or UA response from baseline

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Male

Include criteria

1) newly diagnosed prostate cancer in low risk patients
2) initial PSA less than 10, and T2
3) patients with informed consent in this research
4) male patients older than 20
5) patients with less than ECOG PS 1

Exclude criteria

patients in dementia
patients with severe infection
patients with hepatic dysfunction
patients with renal disorders
patients who was recognized as inadequate in this test by doctors

Related Information

• Primary Sponsor: Naiki-Ito Aya